FDA tirzepatide coverage for business development, investment, and market access teams
Lilly’s early JAK data raises myelofibrosis competition question
Medicare GLP-1 coverage 2026: Bridge program starts July 1
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
Novo Nordisk Reports Record Q1 Revenue Driven by Wegovy and Ozempic Demand
FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea
Mounjaro FDA Approval Obesity: Eli Lilly's Tirzepatide Awaits
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
FDA Approves Mounjaro: Key Details on Tirzepatide for Obesity